Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

TP53Mutations and Pathologic Complete Response to Neoadjuvant Cisplatin and Fluorouracil Chemotherapy in Resected Oral Cavity Squamous Cell Carcinoma

(2010) Federica Perrone et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of mutant p53 in human cancer

(2010) Amanda M Goh et al.   JOURNAL OF PATHOLOGY

Rapamycin Prevents Early Onset of Tumorigenesis in an Oral-Specific K-ras and p53 Two-Hit Carcinogenesis Model

(2009) A. R. Raimondi et al.   CANCER RESEARCH

Mutant p53 Drives Invasion by Promoting Integrin Recycling

(2009) Patricia A.J. Muller et al.   CELL

Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer

(2009) J. P. Morton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutant p53 Gain-of-Function in Cancer

(2009) M. Oren et al.   Cold Spring Harbor Perspectives in Biology

TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use

(2009) M. Olivier et al.   Cold Spring Harbor Perspectives in Biology

Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer

(2008) Nur Mohammad Monsur Hassan et al.   CANCER LETTERS